Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

July 22, 2020 11:49 ET | Source: Verona Pharma plc

Closing of Financing, Issued Share Capital and Total Voting Rights

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN OR INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF SUCH JURISDICTION. NEITHER...
July 17, 2020 12:47 ET | Source: Verona Pharma plc

Verona Pharma plc: PDMR Dealings

LONDON, United Kingdom and RALEIGH, N.C., July 17, 2020 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM: VRP) (Nasdaq: VRNA) (“Verona Pharma” or the “Company”), a clinical-stage biopharmaceutical company...
July 17, 2020 02:00 ET | Source: Verona Pharma plc

Verona Pharma Raises $200 Million in Oversubscribed Private Placement and Subscription

THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF THE MARKET ABUSE REGULATION (EU) NO. 596/2014 (“MAR”). UPON PUBLICATION OF THIS ANNOUNCEMENT THIS INFORMATION IS NOW...
July 06, 2020 11:04 ET | Source: Verona Pharma plc

Verona Pharma plc: Issue of Equity and Total Voting Rights

LONDON, July 06, 2020 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM:VRP) (Nasdaq:VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative...
May 14, 2020 02:00 ET | Source: Verona Pharma plc

Verona Pharma Announces FDA Response to End-of-Phase 2 Briefing Package for Ensifentrine in COPD and Outlines Phase 3 ENHANCE Clinical Program

LONDON, May 14, 2020 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM: VRP) (Nasdaq: VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on respiratory diseases, announces that it...
May 12, 2020 08:11 ET | Source: Verona Pharma plc

Director/PDMR Shareholding - Grant of Restricted Stock Units, Issue of Equity, Total Voting Rights & PDMR Dealings

LONDON, May 12, 2020 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM:VRP) (Nasdaq:VRNA) (“Verona Pharma” or the “Company”), a clinical-stage biopharmaceutical company focused on developing and...
May 01, 2020 12:12 ET | Source: Verona Pharma plc

Verona Pharma Presents Expanded Analysis of Ensifentrine Clinical Data in COPD Maintenance Treatment at the American Thoracic Society 2020 International Conference

Analysis supports ensifentrine’s efficacy in COPD as monotherapy and on top of standard of care treatment in patients who remain symptomatic Six abstracts accepted demonstrating ensifentrine’s...
April 30, 2020 02:00 ET | Source: Verona Pharma plc

Verona Pharma plc: Operational Update and Financial Results for the Three Months Ended March 31, 2020

Reported positive Phase 2b results in symptomatic patients with moderate to severe COPD with nebulized ensifentrine Reported positive efficacy and safety with single dose pMDI ensifentrine U.S. FDA...
April 23, 2020 02:00 ET | Source: Verona Pharma plc

Verona Pharma to Announce Financial Results for the Three Months Ended March 31, 2020 and Provide Corporate Update

LONDON, April 23, 2020 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM: VRP) (Nasdaq: VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on respiratory diseases, announces that...
April 16, 2020 07:12 ET | Source: Verona Pharma plc

Verona Pharma plc: Results of AGM

LONDON, April 16, 2020 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM: VRP) (Nasdaq: VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on developing and commercializing...